BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aldunate F, Echeverría N, Chiodi D, López P, Sánchez-Cicerón A, Fajardo A, Soñora M, Cristina J, Hernández N, Moreno P. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients. Dis Markers 2018;2018:2514901. [PMID: 30186532 DOI: 10.1155/2018/2514901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lashgarian HE, Valibeik A, Marzban A, Karkhane M, Shahzamani K. The Relationship Between HCV-NS5A Gene Mutations and Resistance to Combination Therapy in Patients with HCV- Genotype 1-B. Rep Biochem Mol Biol 2021;10:233-42. [PMID: 34604413 DOI: 10.52547/rbmb.10.2.233] [Reference Citation Analysis]
2 Eybpoosh S, Kiminezhad Malaie M. Comment on "Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients". Dis Markers 2018;2018:8698263. [PMID: 30524522 DOI: 10.1155/2018/8698263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Hasanshahi Z, Hashempour A, Ghasabi F, Moayedi J, Musavi Z, Dehghani B, Sharafi H, Joulaei H. First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. BMC Gastroenterol 2021;21:443. [PMID: 34819046 DOI: 10.1186/s12876-021-01988-y] [Reference Citation Analysis]
4 Colon-Moran W, Baer A, Lamture G, Stapleton JT, Fischer JW, Bhattarai N. A short hepatitis C virus NS5A peptide expression by AAV vector modulates human T cell activation and reduces vector immunogenicity. Gene Ther 2021. [PMID: 34759330 DOI: 10.1038/s41434-021-00302-5] [Reference Citation Analysis]
5 Abergel A, Asselah T, Mallat A, Chanteranne B, Faure F, Larrey D, Gournay J, Loustaud-Ratti V, Di Martino V, Fouchard-Hubert I, Pol S, Bailly F, Samuel D, Tran A, Dodel M, Andant N, Lamblin G, Muti L, Reymond M, Teilhet C, Pereira B, Buchard B. Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. Liver Int 2020;40:1853-9. [PMID: 32383275 DOI: 10.1111/liv.14502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
6 Rahimi P, Sharafi H, Bahramali G, SajadianFard F, Asadi NS, Alavian SM, Iranpur Mobarakeh V, Moravej SZ. Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection. Front Microbiol 2020;11:617375. [PMID: 33584581 DOI: 10.3389/fmicb.2020.617375] [Reference Citation Analysis]
7 Aldunate F, Echeverría N, Chiodi D, López P, Sánchez-Cicerón A, Fajardo A, Soñora M, Cristina J, Hernández N, Moreno P. Response to: Comment on "Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients". Dis Markers 2019;2019:2520302. [PMID: 30867847 DOI: 10.1155/2019/2520302] [Reference Citation Analysis]
8 Martínez AP, García G, Ridruejo E, Culasso AC, Pérez PS, Pereson MJ, Neukam K, Flichman D, Di Lello FA. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina. J Med Virol 2019;91:1970-8. [PMID: 31273794 DOI: 10.1002/jmv.25536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Esposito I, Marciano S, Haddad L, Galdame O, Franco A, Gadano A, Flichman D, Trinks J. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection. Viruses 2018;11:E3. [PMID: 30577623 DOI: 10.3390/v11010003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Ramezani A, Baesi K, Banifazl M, Mohraz M, Khorvash F, Yaran M, Tabarsi P, Dalirrooyfard AH, Motevalli F, Bavand A, Aghakhani A. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population. Clin Res Hepatol Gastroenterol 2019;43:594-602. [PMID: 31080115 DOI: 10.1016/j.clinre.2019.01.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]